PH:NYSEParker-Hannifin Corporation Analysis
Data as of 2026-06-13 - not real-time
$903.48
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Parker‑Hannifin (PH) is trading around $903, comfortably above its 20‑day SMA of $866 but just shy of the 50‑day SMA of $907, indicating a modest short‑term pull‑back risk. Technical momentum remains supportive, with an RSI of 56 (neutral) and a bullish MACD histogram (+8.4) underpinned by increasing volume, while the 30‑day volatility of roughly 27% and a beta near 0.9 suggest moderate price swings. Fundamentally, the company posted solid 10.6% revenue growth, robust operating margins (~21.5%), and free cash flow of $2.77 B, supporting a sustainable dividend (0.89% yield, payout 26.6%). However, the market price far exceeds the DCF‑derived fair value of $383, yielding an upside/downside estimate of only ~14% and a PE of 33 versus the industry average of 30.6, flagging potential overvaluation. Recent earnings commentary highlighted record performance and the addition of flight‑critical motion and flow‑control capabilities expected to generate about $270 M in FY2026 sales, providing a fresh growth catalyst. Nonetheless, the blend of high valuation multiples, cyclical industrial exposure, and modest dividend return tempers enthusiasm. In summary, PH shows strong operational fundamentals and a bullish short‑term technical backdrop, but its premium valuation and sector cyclicality warrant a cautious stance.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD histogram with rising volume
- Price near short‑term support levels
- Overvaluation relative to DCF fair value
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- 10%+ revenue growth and strong operating margins
- New flight‑critical product line adding $270 M FY2026 sales
- Sustainable dividend and solid free cash flow
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Diversified industrial and aerospace portfolio
- Dividend sustainability with low payout ratio
- Valuation premium and cyclicality of industrial demand
Key Metrics & Analysis
Financial Health
Revenue Growth10.60%
Profit Margin16.58%
P/E Ratio33.3
ROE24.84%
ROA9.54%
Debt/Equity65.55
P/B Ratio7.8
Op. Cash Flow$4.1B
Free Cash Flow$2.8B
Industry P/E30.6
Technical Analysis
TrendNeutral
RSI56.5
Support$815.01
Resistance$916.18
MA 20$866.10
MA 50$906.95
MA 200$872.71
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86
Valuation
Fair Value$383.26
Target Price$1,032.24
Upside/Downside14.25%
GradeOvervalued
TypeGrowth
Dividend Yield0.89%
Risk Assessment
Beta0.92
Volatility26.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.